Q-omics provides the consensus-scored BACE1-AS profile across patient tissues and cancer cell-line models. BACE1-AS expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BACE1-AS is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, BACE1-AS RNA expression shows 19,971 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where BACE1-AS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BACE1-AS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BACE1-AS survival associations across molecular data types. BACE1-AS RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BACE1-AS RNA expression–survival associations across cancer types. High BACE1-AS expression shows unfavorable associations in ACC, LIHC, KIRC and DLBC, but favorable associations in HNSC and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BACE1-AS RNA expression.
This table summarizes BACE1-AS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for BACE1-AS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BACE1-AS shows lower tumor expression in UCEC and BRCA and higher tumor expression in LIHC, KIRC, CHOL and STAD. The LIHC box plot shows higher BACE1-AS RNA expression in tumor versus normal tissue (log2 FC = +1.617, t-test p < 0.001).
This table shows molecular features associated with BACE1-AS in patient tissues and cancer cell lines. In patient samples, BACE1-AS shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
